**Flex Pharma received FDA approval for NDA217379 on May 29, 2026, a milestone anticipated to unlock significant commercial value and drive a material re-rating of the company’s market capitalization.** *(Note: The "Substance" field in your input was empty. If you can provide the drug name/therapy area, the market implications can be more specific.)*